Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib

PURPOSE: Rhabdomyosarcomas (RMS) are difficult tumors to treat with conventional therapies. Publications indicate that oncolytic virotherapy (OV) could benefit cancer patients with tumors that are refractory to conventional treatments. It is believed that the efficacy of OV can be enhanced when used...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashton, Laura V, Graham, Barbara, Afzali, Maryam F, Gustafson, Daniel, MacNeill, Amy L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266523/
https://www.ncbi.nlm.nih.gov/pubmed/32548076
http://dx.doi.org/10.2147/OV.S252727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266523/
https://www.ncbi.nlm.nih.gov/pubmed/32548076
http://dx.doi.org/10.2147/OV.S252727

Ejemplares similares